Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when AOD-9604 crosses your target, drops, or sets a new tracked low—without daily noise.

Price scope Alert me Target per mg

$/mg

Confirmed Weekly Peptide Intel email

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.

Public product evidence 160 certificate records for AOD-9604 products, from 60 vendors 94 reference a report on the testing laboratory's own system · 75 have a laboratory lookup that answered when last checked · 151 match a vendor product page at the same address

Status

Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area

Metabolic / incretin research

This profile is grouped by its dominant research area, not by vendor shelf placement.

Aliases

Advanced Obesity Drug-9604

Signal depth

Low

No FDA label signal · 0 trials · 12 PubMed results

Preclinical

Research evidence

Current evidence for AOD-9604 is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

AOD-9604 has no clinical trials that name it and 12 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data

Lab / animal only

Trial quality

No human trials

Outcomes

No human trials

Replication

Multiple papers

Literature

Emerging

PubMed · 3 citations AOD-9604 Metabolic. Inpharma Weekly The orally active peptide AOD 9604* may aid weight reduction in obese subjects, Inpharma Weekly The anti-obesity drug AOD-9604* has demonstrated favourable safety and tolerability in a phase II clinical trial. Journal Article Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Journal Article Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal Article Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-03 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What AOD-9604 is

AOD-9604 is a modified fragment of human growth hormone built around amino acids 176-191. It is usually discussed as a body-composition or weight-management compound rather than as a classic growth-hormone replacement medicine.

Why people track it

The compound shows up often in peptide conversations because it is framed as a metabolic or lipolytic fragment rather than a full GH analog. That distinction is part of the marketing story around it, but it is not the same thing as having an FDA-approved obesity indication.

Regulatory context

AOD-9604 is not an FDA-approved drug in the United States. On this site it belongs in the research-market bucket, not the approved-medicine bucket.

Practical reading note

If you see aggressive claims around AOD-9604, the useful questions are:

what jurisdiction is being referenced
whether the seller is describing a research product or a regulated medicine
and whether any claimed outcome is coming from robust human evidence or from broader peptide-marketing language